| First Author | Qiao J | Year | 2019 |
| Journal | Cancer Cell | Volume | 35 |
| Issue | 6 | Pages | 901-915.e4 |
| PubMed ID | 31185213 | Mgi Jnum | J:276335 |
| Mgi Id | MGI:6314459 | Doi | 10.1016/j.ccell.2019.05.005 |
| Citation | Qiao J, et al. (2019) Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8(+) T Cell Apoptosis. Cancer Cell 35(6):901-915.e4 |
| abstractText | Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cytokine, induces antitumor effects depending on CD8(+) T cells. However, it remains elusive how immunosuppressive effects of IL-10 contribute to CD8(+) T cell-mediated antitumor immunity. We generated Cetuximab-based IL-10 fusion protein (CmAb-(IL10)2) to prolong its half-life and allow tumor-targeted delivery of IL-10. Our results demonstrated potent antitumor effects of CmAb-(IL10)2 with reduced toxicity. Moreover, we revealed a mechanism of CmAb-(IL10)2 preventing dendritic cell (DC)-mediated CD8(+) tumor-infiltrating lymphocyte apoptosis through regulating IFN-gamma production. When combined with immune checkpoint blockade, CmAb-(IL10)2 significantly improves antitumor effects in mice with advanced tumors. Our findings reveal a DC-regulating role of IL-10 to potentiate CD8(+) T cell-mediated antitumor immunity and provide a potential strategy to improve cancer immunotherapy. |
